Purpose In multiple cell metazoans, the ability of polarized epithelial cells to convert to
motile mesenchymal cells in order to relocate to another location is governed by a unique …

Despite high initial efficacy, targeted therapies eventually fail in advanced cancers, as
tumors develop resistance and relapse. In contrast to the substantial body of research on the …

Drug resistance constitutes a major challenge in designing melanoma therapies.
Microenvironment-driven tumor heterogeneity and plasticity play a key role in this …

Therapy resistance is a characteristic of cancer cells that significantly reduces the
effectiveness of drugs. Despite the popularity of cisplatin (CP) as a chemotherapeutic agent …

Cancers develop in complex tissue environments, which they depend on for sustained
growth, invasion and metastasis. Unlike tumor cells, stromal cell types within the tumor …

Tumor microenvironment (TME) is a host for a complex network of heterogeneous stromal
cells with overlapping or opposing functions depending on the dominant signals within this …

A bottleneck that is hindering therapeutics innovation in cancers is the current lack of
integration of what we have learned in tumor biology as well as the tumor microenvironment …

Recent advances in cancer immunology have led to a better understanding of the role of the
tumor microenvironment (TME) in tumor initiation, progression, and metastasis. Tumors can …

A current challenge in cancer treatment is drug resistance. Even the most effective therapies
often fail to produce a complete and durable tumor response and ultimately give rise to …

Recent advances in cancer therapy encounter a bottleneck. Relapsing/recurrent disease
almost always developed eventually with resistance to the initially effective drugs. Tumor …